Blog

Contains articles from Dante and our partners discussing the latest research, publications, and updates about genome sequencing.
dante genomics dna sequencing
Diagnostics

TMA Precision Health and Dante Genomics partner to help children with rare diseases through clinical whole genome sequencing solutions

Dante Genomics is a global genomic information company building and commercializing a new class of transformative health and longevity applications based on whole genome sequencing and AI. The Company uses its platform to deliver better patient outcomes from diagnostics to therapeutics with assets including one of the largest private genome databases with research consent, proprietary software designed to unleash the power of genomic data at scale and proprietary processes which enable an industrial approach to genomic sequencing.

Read More ➝
Tasso M-20 kit
About Us

Dante Genomics to innovate universal genomics by now offering easy, at-home blood collection kits for clinical whole genome sequencing without the use of a needle

Dante Genomics, a global leader in genomics and precision medicine, today announced that members of its management team will participate in the Canaccord Genuity 42nd Annual Growth Conference, and Andrea Riposati, CEO of Dante Genomics, will participate in a panel presentation on leveraging omics-based data and analytics to advance precision health to the next level on Thursday, August 11, 2022 at 9:30 AM Eastern Time.

Read More ➝
image dante genomics logo and canaccord genuity logo
About Us

Dante Genomics to Participate in a Panel Presentation at the Canaccord Genuity 42nd Annual Growth Conference

Dante Genomics, a global leader in genomics and precision medicine, today announced that members of its management team will participate in the Canaccord Genuity 42nd Annual Growth Conference, and Andrea Riposati, CEO of Dante Genomics, will participate in a panel presentation on leveraging omics-based data and analytics to advance precision health to the next level on Thursday, August 11, 2022 at 9:30 AM Eastern Time.

Read More ➝
image mainz biomed dante
Diagnostics

Mainz Biomed & Dante Labs Announce Partnership for the Commercialization of ColoAlert in Europe and the United Arab Emirates (UAE)

Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer and Dante Labs, a global leader in genomics and precision medicine, announced today a partnership for the commercialization of ColoAlert in Italy and the United Arab Emirates (UAE). ColoAlert is Mainz’s flagship product, a highly efficacious and easy to use at-home detection test for colorectal cancer (CRC).

Read More ➝
Genome Sequencing

Dante Labs receives grant by Italian government to pilot revolutionary CE-IVD, clinical whole genome sequencing-based Citizen Test for a G7 country, starting a new era in clinical genomics

Dante Labs, a global leader in genomics and precision medicine, is pleased to announce the Italian Ministry of Economic Development has selected Dante to develop and pilot the first fully-CE-IVD, clinically approved whole genome sequencing (WGS) test for the citizens of Italy to be named the Dante Citizen Test.

Read More ➝